PEPTIDEATLAS / LIBRARY
Retatrutide: trials and approval status
Retatrutide explained: triple-receptor mechanism, Phase 3 trial context, current approval status and how to read the evidence.
Mechanism and research context
A triple receptor agonist studied in obesity and related conditions. Lilly describes it as an investigational molecule that is not yet approved for use.
Continue reading
How to assess the evidence
Check the trial, participant population, duration and comparison. Consider adverse events and discontinuations alongside the measured effect.
Results for a combination do not automatically apply to either component alone. Separate trials are not a head-to-head comparison.
What the results do not establish
Clinical findings do not establish the composition or quality of an online shop product. This profile provides no individual treatment, dosing or use instructions.
Primary source checked: 2026-09-22. Not presented as independently medically reviewed.